Cargando…
Fibrinolytics as an ARDS Salvage Option: Promising, But ARDS Prevention Options Are Needed Urgently
Autor principal: | Cap, Andrew P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Chest Physicians
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767759/ https://www.ncbi.nlm.nih.gov/pubmed/35063416 http://dx.doi.org/10.1016/j.chest.2021.11.022 |
Ejemplares similares
-
COVID-19 pneumonia: ARDS or not?
por: Gattinoni, Luciano, et al.
Publicado: (2020) -
Fibrinolytic therapy in patients with COVID-19 and ARDS: protocol for a systematic review and meta-analysis
por: Savioli, Felicio, et al.
Publicado: (2023) -
Why and how do we need comprehensive international clinical epidemiology of ARDS?
por: Tognoni, Gianni, et al.
Publicado: (2021) -
Lung targeted liposomes for treating ARDS
por: Arber Raviv, Sivan, et al.
Publicado: (2022) -
Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID‐19
por: Whyte, Claire S., et al.
Publicado: (2020)